Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in Philadelphia, Pennsylvania.…
Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb
Iovance Biotherapeutics (NASDAQ: IOVA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 975 employees.
The shares were at 6.900 USD on 20 November 2026, up 200.0% over 52 weeks. Its 52-week range is 2.080 USD to 15.37 USD: the price is 55.1% below the high and 231.7% above the low.
Its market capitalisation is 3.19B USD.
Iovance Biotherapeutics reports return on equity of -56.0%, an operating margin of -60.8% and revenue up 80.1% year over year.
It holds more cash than debt, a net cash position of 331.11M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 10 analysts cover the stock, with an average rating of Buy; their mean price target of 14.50 USD is 110.1% above the current price. The next earnings report is expected on 23 February 2027.